Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes Using Alzheimer's Disease Biofluid, PET, Postmortem Pathology Biomarkers, and APOE Genotype.

International journal of molecular sciences - 19 Sept 2024

Kara Firat, Kantarci Kejal

Abstract excerpt

In vivo proton (1H) magnetic resonance spectroscopy (MRS) is a powerful non-invasive method that can measure Alzheimer's disease (AD)-related neuropathological alterations at the molecular level. AD biomarkers include amyloid-beta (Aβ) plaques and hyperphosphorylated tau neurofibrillary tangles. These biomarkers can be detected via postmortem analysis but also in living individuals through positron emission...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Peptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoproteins E

Share to Biomarkers

Share to Positron-Emission Tomography

Share to Proton Magnetic Resonance Spectroscopy

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 39337551
DOI: 10.3390/ijms251810064
PMCID: PMC11432594

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes Using Alzheimer's Disease Biofluid, PET, Postmortem Pathology Biomarkers, and APOE Genotype.PMID 39337551Read ↗

Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes using Alzheimer’s Disease Biofluid, PET, Postmortem Pathology Biomarkers and APOE GenotypeSemantic proximity Read ↗

Biomarkers for Alzheimer's disease.Semantic proximity Read ↗

CSF metabolites associated with biomarkers of Alzheimer’s disease pathologySemantic proximity Read ↗

Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopySemantic proximity Read ↗

Novel biomarkers in Alzheimer’s disease using high resolution proteomics and metabolomics: miRNAS, proteins and metabolitesSemantic proximity Read ↗

CSF metabolites associated with biomarkers of Alzheimer’s disease pathologySemantic proximity Read ↗

Differences in Plasma Metabolites Related to Alzheimer’s Disease, APOE-ε4 status and EthnicitySemantic proximity Read ↗

Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent InsightsSemantic proximity Read ↗

Next-generation biomarker discovery in Alzheimer's disease using metabolomics - from animal to human studies.Semantic proximity Read ↗

Decreased brain pH correlated with progression of Alzheimer’s disease neuropathology: a systematic review and meta-analyses of postmortem studiesSemantic proximity Read ↗

An 1H-MRS framework predicts the onset of Alzheimer's disease symptoms in PSEN1 mutation carriers.Semantic proximity Read ↗

Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.